Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults

Vaccine

Volumn 31, Issue 36, 2013, Pages 3688-3694

  Soonawala, Darius ^a   Verdijk, Pauline ^b,c   Wijmenga Monsuur, Alienke J ^b   Boog, Claire J ^b,c   Koedam, Patrick ^d   Visser, Leo G ^a   Rots, Nynke Y ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c Intravacc   (Netherlands)

^d NETHERLANDS VACCINE INSTITUTE   (Netherlands)

Author keywords

Intradermal; Jet injector; Needle free; Polio; Vaccination

Indexed keywords

INACTIVATED VACCINE; NEUTRALIZING ANTIBODY; POLIOMYELITIS VACCINE;

ADULT; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DILUTION; DRUG TOLERABILITY; FEMALE; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE SWELLING; JET INJECTOR; MALE; NEEDLE; POLIOMYELITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SKIN INDURATION; VACCINATION; VOLUNTEER;

INTRADERMAL; JET INJECTOR; NEEDLE-FREE; POLIO; VACCINATION;

ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY FORMATION; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; INJECTIONS, INTRADERMAL; INJECTIONS, INTRAMUSCULAR; INJECTIONS, JET; MALE; NETHERLANDS; POLIOMYELITIS; POLIOVIRUS VACCINE, INACTIVATED; VACCINATION; YOUNG ADULT;

EID: 84880930924     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.05.104     Document Type: Article

References (24)

1. Global Polio Eradication Initiative - Strategic Plan 2010-2012. WHO; 2010. Available from: [accessed 07.08.12]. http://www.polioeradication.org/content/publications/GPEI.%20StrategicPlan.2010-2012.ENG.%20May.2010.pdf.
2. Minor P. Vaccine-derived poliovirus (VDPV): impact on poliomyelitis eradication. Vaccine 2009, 27:2649-2652.
3. Aylward R.B., Sutter R.W., Heymann D.L. Policy. OPV cessation-the final step to a "polio-free" world. Science 2005, 310:625-626.
4. Conclusions and recommendations of the Advisory Committee on Poliomyelitis Eradication, Geneva, November 27-28, 2007. Wkly Epidemiol Rec 2008;83:25-35.
5. Mohammed A.J., AlAwaidy S., Bawikar S., Kurup P.J., Elamir E., Shaban M.M., et al. Fractional doses of inactivated poliovirus vaccine in Oman. N Engl J Med 2010, 362:2351-2359.
6. Kupper T.S., Fuhlbrigge R.C. Immune surveillance in the skin: mechanisms and clinical consequences. Nat Rev Immunol 2004, 4:211-222.
7. Nicolas J.F., Guy B. Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice. Expert Rev Vaccines 2008, 7:1201-1214.
8. Redfield R.R., Innis B.L., Scott R.M., Cannon H.G., Bancroft W.H. Clinical evaluation of low-dose intradermally administered hepatitis B virus vaccine. A cost reduction strategy. J Am Med Assoc 1985, 254:3203-3206.
9. Nelson K.S., Janssen J.M., Troy S.B., Maldonado Y. Intradermal fractional dose inactivated polio vaccine: a review of the literature. Vaccine 2012, 30:121-125.
10. Cadorna-Carlos J., Vidor E., Bonnet M.C. Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. Int J Infect Dis 2012, 16:e110-e116.
11. Dayan G.H., Thorley M., Yamamura Y., Rodriguez N., McLaughlin S., Torres L.M., et al. Serologic response to inactivated poliovirus vaccine: a randomized clinical trial comparing 2 vaccination schedules in Puerto Rico. J Infect Dis 2007, 195:12-20.
12. Krishnan R., Jadhav M., John T.J. Efficacy of inactivated poliovirus vaccine in India. Bull World Health Organ 1983, 61:689-692.
13. Resik S., Tejeda A., Lago P.M., Diaz M., Carmenates A., Sarmiento L., et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba. J Infect Dis 2010, 201:1344-1352.
14. Manual for the virological investigation of polio. WHO/EPI/GEN 97.01. WHO; 1997.
15. Diedrich S., Claus H., Schreier E. Immunity status against poliomyelitis in Germany: determination of cut-off values in International Units. BMC Infect Dis 2002, 2:2.
16. Committee for Medicinal Products for Human Use (CHMP) guideline on the choice of the non-inferiority margin. Stat Med 2006;25:1628-38.
17. Rumke H., Labadie J., Elzinga-Gholizadea N., Mensinga T. IPV-Vero vaccine induces a strong booster reaction and is well tolerated in adults. Scand J Infect Dis 1998, 30:535-538.
18. Grimprel E., von Sonnenburg F., Sanger R., Abitbol V., Wolter J.M., Schuerman L.M. Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults. Vaccine 2005, 23:3657-3667.
19. Piaggio G., Elbourne D.R., Altman D.G., Pocock S.J., Evans S.J. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. J Am Med Assoc 2006, 295:1152-1160.
20. Simon J.K., Carter M., Pasetti M.F., Sztein M.B., Kotloff K.L., Weniger B.G., et al. Safety, tolerability, and immunogenicity of inactivated trivalent seasonal influenza vaccine administered with a needle-free disposable-syringe jet injector. Vaccine 2011, 29:9544-9550.
21. Resik S., Tejeda A., Sutter R.W., Diaz M., Sarmiento L., Alemañi N., et al. Priming after a fractional dose of inactivated poliovirus vaccine. N Engl J Med 2013, 368:416-424.
22. Estivariz C.F., Jafari H., Sutter R.W., John T.J., Jain V., Agarwal A., et al. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6-9 months in Moradabad, India: a community-based, randomised controlled trial. Lancet Infect Dis 2012, 12:128-135.
23. Salk J. One-dose immunization against paralytic poliomyelitis using a noninfectious vaccine. Rev Infect Dis 1984, 6(Suppl. 2):S444-S450.
24. Salk D., van Wezel A.L., Salk J. Induction of long-term immunity to paralytic poliomyelitis by use of non-infectious vaccine. Lancet 1984, 2:1317-1321.